Clinical Trial Detail

NCT ID NCT03190174
Title Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Sarcoma Oncology Research Center, LLC
Indications

chondrosarcoma

Ewing sarcoma

malignant fibroxanthoma

osteosarcoma

liposarcoma

Therapies

Nab-Rapamycin + Nivolumab

Age Groups: adult senior

No variant requirements are available.